Johnson & Johnson
JNJ#28 of 134 by buybacksNYSE · Healthcare · Drug Manufacturers - General · USA
jnj.comBuybacks · TTM to Jun 2026$8.07Blatest four quarters
Buyback yield1.3%repurchases ÷ market cap
Dividends · TTM to Jun 2026$12.6Bdividend yield 2.0%
Shareholder yield3.3%buybacks + dividends ÷ market cap
Shares outstanding · 5 yr−8.6%2.44B shares (2026)
Buybacks ÷ free cash flow43%payout incl. dividends 111%
Fiscal-year detail
From the cash-flow statement as reported, in USD. Negative repurchases mean net share issuance.
| Fiscal year | Repurchases | Dividends | Free cash flow |
|---|---|---|---|
| FY2025Dec 2025 | $5.95B | $12.4B | $19.7B |
| FY2024Dec 2024 | $2.43B | $11.8B | $19.8B |
| FY2023Dec 2023 | $5.05B | $11.8B | $18.2B |
| FY2022Dec 2022 | $6.04B | $11.7B | $17.2B |
| FY2021Dec 2021 | $3.46B | $11.0B | $19.8B |
| FY2020Dec 2020 | $3.22B | $10.5B | $20.2B |
| FY2019Dec 2019 | $6.75B | $9.92B | $19.9B |
Repurchases in FY2025 were +144.8% versus the prior year.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare…
- Market cap
- $630B
- P/E (trailing)
- 30.3×
- Fiscal year end
- December
- ISIN
- US4781601046
- Reporting currency
- USD
- Data updated
- Oct 10, 2026